FerriScan® Results Are Not Confounded by Liver Fat
- 19 April 2017
Recent study results have demonstrated that FerriScan, the globally recognised gold standard for the measurement of liver iron concentration (LIC), is not confounded by the presence of liver steatosis. This places FerriScan at a distinct advantage to alternative magnetic resonance imaging (MRI) LIC assessment techniques, such as liver T2*, whose results are impacted by the presence of fat due to the inherent nature of the technique.
Resonance Health News - March 2017
- 31 March 2017
We are delighted to release our first newsletter of the calender year, in what has already been a very busy start to 2017. We look forward to further progressing in our endeavours and welcome your ongoing participation.
To view the newsletter please click here...
Survey Results: Transfusional Iron Overload and Cancer Survivors
- 30 March 2017
Following the publication of several studies discussing the occurrence of transfusional iron overload in cancer survivors, Resonance Health asked specialist healthcare providers to complete a survey on clinical practice in monitoring and treating iron overload in this cohort. The survey response was excellent and as such is considered a valid snapshot of current practice.
Cancer Survivorship Conferences
- 30 March 2017
Resonance Health is actively involved in exploring and promoting awareness of the risk of iron toxicity and fatty liver in cancer survivors, which has resulted from cancer treatment regimes. We are working with healthcare providers, patient advocacy groups, health institutions, and patients, to assist with the provision of optimal patient care. Recently, we have attended two conferences targeted towards cancer survivorship; the Cancer Survivorship Summit in the UK and the Cancer Survivor Meeting in the USA.
American Society of Hematology (ASH) Annual Meeting Update
- 15 December 2016
Several presentations were delivered by independent experts at the prestigious 58th ASH Annual Meeting that summarised studies using Resonance Health’s FerriScan® technology. The studies demonstrated the broadening acceptance of FerriScan in iron monitoring and management and included results from the multicentre US TWiTCH study (click here to read the abstract) and from China’s Guangxi Medical University (click here to read the abstract).
Results Published Recommending Use of FerriScan in Sickle Cell Disease
- 10 November 2016
FerriScan has received further endorsement for the management of patients with Sickle Cell Disease (SCD) in apaper recently published by the highly respected Dr Janet Kwiatkowski team at the Children’s Hospital of Philadelphia, USA.